Global Nonalcoholic Steatohepatitis Therapeutics Market Report 2023 Featuring Pfizer, Inventiva, - Benzinga

GLMD Stock  USD 3.43  0.11  3.31%   
About 55% of Galmed Pharmaceuticals' shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding Galmed Pharmaceuticals suggests that some traders are interested. The current market sentiment, together with Galmed Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Galmed Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
Global Nonalcoholic Steatohepatitis Therapeutics Market Report 2023 Featuring Pfizer, Inventiva, Benzinga

Read at news.google.com
Google News at Macroaxis
  

Galmed Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Galmed Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Galmed Pharmaceuticals Fundamental Analysis

We analyze Galmed Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galmed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galmed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Short Ratio

Short Ratio Comparative Analysis

Galmed Pharmaceuticals is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.

Galmed Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Galmed Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Galmed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Galmed Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Galmed Pharmaceuticals Related Equities

MREOMereo BioPharma   9.06   
0%
100.0%
KODKodiak Sciences   5.80   
0%
64.0%
FBIOFortress Biotech   5.19   
0%
57.0%
ADAPAdaptimmune Therapeutics   4.84   
0%
53.0%
MBIOMustang Bio   4.76   
0%
52.0%
ADVMAdverum Biotechnologies   4.38   
0%
48.0%
APTOAptose Biosciences   4.35   
0%
48.0%
PDSBPDS Biotechnology   4.05   
0%
44.0%
LPTXLeap Therapeutics   4.04   
0%
44.0%
ABEOAbeona Therapeutics   1.86   
0%
20.0%
ACHLAchilles Therapeutics   1.75   
0%
19.0%
AKBAAkebia Ther   1.05   
0%
11.0%
AFMDAffimed NV   0.74   
0%
8.0%
FBIOPFortress Biotech   1.31   
14.0%
0%

Complementary Tools for Galmed Stock analysis

When running Galmed Pharmaceuticals' price analysis, check to measure Galmed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galmed Pharmaceuticals is operating at the current time. Most of Galmed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Galmed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galmed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Galmed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Bonds Directory
Find actively traded corporate debentures issued by US companies
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
CEOs Directory
Screen CEOs from public companies around the world
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm